Exploring predictive biomarkers for lenvatinib and pembrolizumab response in endometrial cancer patients, including NLR, CD20+ B cells, and KEYNOTE-146 findings.
Exploring how biomarkers are transforming the economics of oncology drug development through precision medicine approaches.